{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,5,9]],"date-time":"2026-05-09T15:44:16Z","timestamp":1778341456872,"version":"3.51.4"},"reference-count":25,"publisher":"Springer Science and Business Media LLC","issue":"3","license":[{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"},{"start":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T00:00:00Z","timestamp":1769126400000},"content-version":"vor","delay-in-days":0,"URL":"https:\/\/www.springernature.com\/gp\/researchers\/text-and-data-mining"}],"funder":[{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["19AC1002"],"award-info":[{"award-number":["19AC1002"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/501100003478","name":"Ministry of Health, Labour and Welfare","doi-asserted-by":"publisher","award":["JPMH24FD1001"],"award-info":[{"award-number":["JPMH24FD1001"]}],"id":[{"id":"10.13039\/501100003478","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20ek0210135"],"award-info":[{"award-number":["JP20ek0210135"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP19ek0210095"],"award-info":[{"award-number":["JP19ek0210095"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP20km0405210"],"award-info":[{"award-number":["JP20km0405210"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP23ek0109571"],"award-info":[{"award-number":["JP23ek0109571"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]},{"DOI":"10.13039\/100009619","name":"Japan Agency for Medical Research and Development","doi-asserted-by":"publisher","award":["JP25ek0109812"],"award-info":[{"award-number":["JP25ek0109812"]}],"id":[{"id":"10.13039\/100009619","id-type":"DOI","asserted-by":"publisher"}]}],"content-domain":{"domain":["link.springer.com"],"crossmark-restriction":false},"short-container-title":["Clin Exp Nephrol"],"published-print":{"date-parts":[[2026,3]]},"DOI":"10.1007\/s10157-025-02799-1","type":"journal-article","created":{"date-parts":[[2026,1,23]],"date-time":"2026-01-23T14:46:09Z","timestamp":1769179569000},"page":"424-433","update-policy":"https:\/\/doi.org\/10.1007\/springer_crossmark_policy","source":"Crossref","is-referenced-by-count":1,"title":["Association between early proteinuria reduction and kidney outcomes in Japanese patients with IgA nephropathy: The Japan Chronic Kidney Disease Database"],"prefix":"10.1007","volume":"30","author":[{"given":"Yuichiro","family":"Yano","sequence":"first","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hajime","family":"Nagasu","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hiroshi","family":"Kanegae","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Seiji","family":"Itano","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Masaomi","family":"Nangaku","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hitoshi","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Mizuki","family":"Ohashi","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Hirokazu","family":"Okada","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Yusuke","family":"Suzuki","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]},{"given":"Naoki","family":"Kashihara","sequence":"additional","affiliation":[],"role":[{"role":"author","vocabulary":"crossref"}]}],"member":"297","published-online":{"date-parts":[[2026,1,23]]},"reference":[{"key":"2799_CR1","doi-asserted-by":"publisher","first-page":"2402","DOI":"10.1056\/NEJMra1206793","volume":"368","author":"RJ Wyatt","year":"2013","unstructured":"Wyatt RJ, Julian BA. IgA nephropathy. N Engl J Med. 2013;368:2402\u201314.","journal-title":"N Engl J Med"},{"issue":"6","key":"2799_CR2","doi-asserted-by":"publisher","first-page":"727","DOI":"10.2215\/CJN.0000000000000135","volume":"18","author":"D Pitcher","year":"2023","unstructured":"Pitcher D, Braddon F, Hendry B, Mercer A, Osmaston K, Saleem MA, et al. Long-term outcomes in IgA nephropathy. Clin J Am Soc Nephrol. 2023;18(6):727\u201338.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2799_CR3","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson A, Carroll K, Ai L, Woodward M, Perkovic V, Jardine MJ. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14:469\u201381.","journal-title":"Clin J Am Soc Nephrol"},{"key":"2799_CR4","doi-asserted-by":"publisher","first-page":"340","DOI":"10.1053\/j.ajkd.2021.03.007","volume":"78","author":"LA Inker","year":"2021","unstructured":"Inker LA, Heerspink HJL, Tighiouart H, Chaudhari J, Miao S, Diva U, et al. Association of treatment effects on early change in urine protein and treatment effects on GFR slope in IgA nephropathy: an individual participant meta-analysis. Am J Kidney Dis. 2021;78:340\u2013349.e1.","journal-title":"Am J Kidney Dis"},{"issue":"3","key":"2799_CR5","doi-asserted-by":"publisher","first-page":"469","DOI":"10.2215\/CJN.08600718","volume":"14","author":"A Thompson","year":"2019","unstructured":"Thompson A, Carroll K, Inker LA, Floege J, Perkovic V, Boyer-Suavet S, et al. Proteinuria reduction as a surrogate end point in trials of IgA nephropathy. Clin J Am Soc Nephrol. 2019;14(3):469\u201381.","journal-title":"Clin J Am Soc Nephrol"},{"issue":"3","key":"2799_CR6","doi-asserted-by":"publisher","first-page":"392","DOI":"10.1053\/j.ajkd.2016.02.042","volume":"68","author":"LA Inker","year":"2016","unstructured":"Inker LA, Mondal H, Greene T, Masaschi T, Locatelli F, Schena FP, et al. Early change in urine protein as a surrogate end point in studies of IgA nephropathy: an individual-patient meta-analysis. Am J Kidney Dis. 2016;68(3):392\u2013401.","journal-title":"Am J Kidney Dis"},{"issue":"10388","key":"2799_CR7","doi-asserted-by":"publisher","first-page":"1584","DOI":"10.1016\/S0140-6736(23)00569-X","volume":"401","author":"HJL Heerspink","year":"2023","unstructured":"Heerspink HJL, Radhakrishnan J, Alpers CE, Barratt J, Bieler S, Diva U, et al. Sparsentan in patients with IgA nephropathy: a prespecified interim analysis from a randomised, double-blind, active-controlled clinical trial. Lancet. 2023;401(10388):1584\u201394.","journal-title":"Lancet"},{"issue":"10417","key":"2799_CR8","doi-asserted-by":"publisher","first-page":"2077","DOI":"10.1016\/S0140-6736(23)02302-4","volume":"402","author":"BH Rovin","year":"2023","unstructured":"Rovin BH, Barratt J, Heerspink HJL, Alpers CE, Bieler S, Chae DW, et al. Efficacy and safety of sparsentan versus irbesartan in patients with IgA nephropathy (PROTECT): 2-year results from a randomised, active-controlled, phase 3 trial. Lancet. 2023;402(10417):2077\u201390.","journal-title":"Lancet"},{"issue":"3","key":"2799_CR9","doi-asserted-by":"publisher","first-page":"429","DOI":"10.1053\/j.ajkd.2021.01.024","volume":"78","author":"P Pattrapornpisut","year":"2021","unstructured":"Pattrapornpisut P, Avila-Casado C, Reich HN. IgA nephropathy: core curriculum 2021. Am J Kidney Dis. 2021;78(3):429\u201341.","journal-title":"Am J Kidney Dis"},{"issue":"2","key":"2799_CR10","doi-asserted-by":"publisher","first-page":"65","DOI":"10.1111\/nep.14250","volume":"29","author":"Y Yano","year":"2024","unstructured":"Yano Y, Nagasu H, Kanegae H, Nangaku M, Hirakawa Y, Sugawara Y, et al. Kidney outcomes associated with haematuria and proteinuria trajectories among patients with IgA nephropathy in real-world clinical practice: the Japan Chronic Kidney Disease Database. Nephrology. 2024;29(2):65\u201375.","journal-title":"Nephrology"},{"issue":"1","key":"2799_CR11","doi-asserted-by":"publisher","first-page":"sfad294","DOI":"10.1093\/ckj\/sfad294","volume":"17","author":"K Koike","year":"2023","unstructured":"Koike K, Kawamura T, Hirano K, Nishikawa M, Shimizu A, Joh K, et al. Clinicopathological prognostic stratification for proteinuria and kidney survival in IgA nephropathy: a Japanese prospective cohort study. Clin Kidney J. 2023;17(1):sfad294.","journal-title":"Clin Kidney J"},{"issue":"1","key":"2799_CR12","doi-asserted-by":"publisher","first-page":"7351","DOI":"10.1038\/s41598-020-64123-z","volume":"10","author":"N Nakagawa","year":"2020","unstructured":"Nakagawa N, Sofue T, Kanda E, Nagasu H, Matsushita K, Nangaku M, et al. J-CKD-DB: a nationwide multicentre electronic health record-based chronic kidney disease database in Japan. Sci Rep. 2020;10(1):7351.","journal-title":"Sci Rep"},{"issue":"2","key":"2799_CR13","doi-asserted-by":"publisher","first-page":"131","DOI":"10.3414\/ME10-01-0015","volume":"50","author":"M Kimura","year":"2011","unstructured":"Kimura M, Nakayasu K, Ohshima Y, Fujita N, Nakashima N, Jozaki H, et al. SS-MIX: a ministry project to promote standardized healthcare information exchange. Methods Inf Med. 2011;50(2):131\u20139.","journal-title":"Methods Inf Med"},{"issue":"4","key":"2799_CR14","doi-asserted-by":"publisher","first-page":"375","DOI":"10.1007\/s13340-017-0326-y","volume":"8","author":"T Sugiyama","year":"2017","unstructured":"Sugiyama T, Miyo K, Tsujimoto T, Kominami R, Ohtsu H, Ohsugi M, et al. Design of and rationale for the Japan Diabetes compREhensive database project based on an Advanced electronic Medical record System (J-DREAMS). Diabetol Int. 2017;8(4):375\u201382.","journal-title":"Diabetol Int"},{"issue":"1","key":"2799_CR15","doi-asserted-by":"publisher","first-page":"34","DOI":"10.1197\/jamia.M3299","volume":"17","author":"D Rajeev","year":"2010","unstructured":"Rajeev D, Staes CJ, Evans RS, Mottice S, Rolfs R, Samore MH, et al. Development of an electronic public health case report using HL7 v2.5 to meet public health needs. J Am Med Inform Assoc. 2010;17(1):34\u201341.","journal-title":"J Am Med Inform Assoc"},{"issue":"11","key":"2799_CR16","doi-asserted-by":"publisher","first-page":"2542","DOI":"10.2337\/dc21-1081","volume":"44","author":"H Nagasu","year":"2021","unstructured":"Nagasu H, Yano Y, Kanegae H, Heerspink HJL, Nangaku M, Hirakawa Y, et al. Kidney outcomes associated with SGLT2 inhibitors versus other glucose-lowering drugs in real-world clinical practice: the Japan Chronic Kidney Disease Database. Diabetes Care. 2021;44(11):2542\u201351.","journal-title":"Diabetes Care"},{"key":"2799_CR17","doi-asserted-by":"publisher","first-page":"32","DOI":"10.1053\/j.ajkd.2010.02.344","volume":"56","author":"M Horio","year":"2010","unstructured":"Horio M, Imai E, Yasuda Y, Watanabe T, Matsuo S. Modification of the CKD epidemiology collaboration (CKD-EPI) equation for Japanese: accuracy and use for population estimates. Am J Kidney Dis. 2010;56:32\u20138.","journal-title":"Am J Kidney Dis"},{"key":"2799_CR18","first-page":"53","volume":"19","author":"S CoURPTJCfCL","year":"2004","unstructured":"CoURPTJCfCL S. JCCLS document GP 3-P 1 proposed guideline \u201curinary reagent strip method\u201d supplement. Jpn Comm Clin Lab Stand. 2004;19:53\u201365.","journal-title":"Jpn Comm Clin Lab Stand"},{"issue":"6","key":"2799_CR19","doi-asserted-by":"publisher","first-page":"821","DOI":"10.1053\/j.ajkd.2014.07.030","volume":"64","author":"AS Levey","year":"2014","unstructured":"Levey AS, Inker LA, Matsushita K, Greene T, Willis K, Lewis E, et al. GFR decline as an end point for clinical trials in CKD: a scientific workshop sponsored by the National Kidney Foundation and the US Food and Drug Administration. Am J Kidney Dis. 2014;64(6):821\u201335.","journal-title":"Am J Kidney Dis"},{"issue":"6","key":"2799_CR20","doi-asserted-by":"publisher","first-page":"848","DOI":"10.1053\/j.ajkd.2014.08.017","volume":"64","author":"LA Inker","year":"2014","unstructured":"Inker LA, Lambers Heerspink HJ, Mondal H, Schmid CH, Tighiouart H, Noubary F, et al. GFR decline as an alternative end point to kidney failure in clinical trials: a meta-analysis of treatment effects from 37 randomized trials. Am J Kidney Dis. 2014;64(6):848\u201359.","journal-title":"Am J Kidney Dis"},{"issue":"5","key":"2799_CR21","doi-asserted-by":"publisher","first-page":"435","DOI":"10.1016\/j.semnephrol.2018.05.013","volume":"38","author":"FP Schena","year":"2018","unstructured":"Schena FP, Nistor I. Epidemiology of IgA nephropathy: a global perspective. Semin Nephrol. 2018;38(5):435\u201342.","journal-title":"Semin Nephrol"},{"issue":"1","key":"2799_CR22","doi-asserted-by":"publisher","first-page":"215","DOI":"10.1016\/j.kint.2021.03.033","volume":"100","author":"DC Wheeler","year":"2021","unstructured":"Wheeler DC, Toto RD, Stef\u00e1nsson BV, Jongs N, Chertow GM, Greene T, et al. A pre-specified analysis of the DAPA-CKD trial demonstrates the effects of dapagliflozin on major adverse kidney events in patients with IgA nephropathy. Kidney Int. 2021;100(1):215\u201324.","journal-title":"Kidney Int"},{"issue":"3","key":"2799_CR23","doi-asserted-by":"publisher","first-page":"282","DOI":"10.1038\/ki.2011.79","volume":"80","author":"FA Holtkamp","year":"2011","unstructured":"Holtkamp FA, de Zeeuw D, Thomas MC, Cooper ME, de Graeff PA, Hillege HJ, et al. An acute fall in estimated glomerular filtration rate during treatment with losartan predicts a slower decrease in long-term renal function. Kidney Int. 2011;80(3):282\u20137.","journal-title":"Kidney Int"},{"issue":"8","key":"2799_CR24","doi-asserted-by":"publisher","first-page":"1112","DOI":"10.34067\/KID.0000000000000165","volume":"4","author":"K Kiryluk","year":"2023","unstructured":"Kiryluk K, Freedberg DE, Radhakrishnan J, Segall L, Jacobson JS, Mathur M, et al. Global incidence of IgA nephropathy by race and ethnicity: a systematic review. Kidney360. 2023;4(8):1112\u201322.","journal-title":"Kidney360"},{"issue":"9","key":"2799_CR25","doi-asserted-by":"publisher","first-page":"847","DOI":"10.1007\/s10157-024-02514-6","volume":"28","author":"Y Sugawara","year":"2024","unstructured":"Sugawara Y, Kanda E, Hamano T, Itano S, Okada H, Tomori K, et al. Guidelines for clinical evaluation of chronic kidney disease in early stages: AMED research on regulatory science of pharmaceuticals and medical devices. Clin Exp Nephrol. 2024;28(9):847\u201365.","journal-title":"Clin Exp Nephrol"}],"container-title":["Clinical and Experimental Nephrology"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02799-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/article\/10.1007\/s10157-025-02799-1","content-type":"text\/html","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/link.springer.com\/content\/pdf\/10.1007\/s10157-025-02799-1.pdf","content-type":"application\/pdf","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2026,2,28]],"date-time":"2026-02-28T08:11:49Z","timestamp":1772266309000},"score":1,"resource":{"primary":{"URL":"https:\/\/link.springer.com\/10.1007\/s10157-025-02799-1"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2026,1,23]]},"references-count":25,"journal-issue":{"issue":"3","published-print":{"date-parts":[[2026,3]]}},"alternative-id":["2799"],"URL":"https:\/\/doi.org\/10.1007\/s10157-025-02799-1","relation":{},"ISSN":["1342-1751","1437-7799"],"issn-type":[{"value":"1342-1751","type":"print"},{"value":"1437-7799","type":"electronic"}],"subject":[],"published":{"date-parts":[[2026,1,23]]},"assertion":[{"value":"16 September 2025","order":1,"name":"received","label":"Received","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"30 November 2025","order":2,"name":"accepted","label":"Accepted","group":{"name":"ArticleHistory","label":"Article History"}},{"value":"23 January 2026","order":3,"name":"first_online","label":"First Online","group":{"name":"ArticleHistory","label":"Article History"}},{"order":1,"name":"Ethics","group":{"name":"EthicsHeading","label":"Declarations"}},{"value":"Yuichiro Yano received research support, payment or honoraria for lectures, presentations, speakers bureaus, from Kyowa Kirin, Astra Zeneca, Bayer, Boehringer Ingelheim, Otsuka Pharmaceutical Company, Novartis, and Kowa Company. Naoki Kashihara received consulting fees from AstraZeneca, Kyowa Kirin, Novartis, Novo Nordisc, and Daiichi Sankyo, payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Otsuka, Kyowa Kirin, Asterallas, and Ono Pharma, payment for expert testimony from Novartis and Daiichi Sankyo, and a leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid at Japan Kidney Association. Masaomi Nangaku received research support from Kyowa Kirin, Tanabe-Mitsubishi, JT, Chugai, Torii, and Bayer, consulting fees from Kyowa Kirin, Daiichi Sankyo, Tanabe-Mitsubishi, JT, and BI, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Kyowa Kirin, Astra Zeneca, Tanabe-Mitsubishi, and BI. Hitoshi Suzuki received research support from Chugai, Mochida, Kaneka, consulting fees from Viatris, Asahikasei, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Kyowa Kirin, Otsuka, Astra Zeneca, Novartis. Hirokazu Okada received research support from Kyowa Kirin, Bayer Pharm, Chugai Pharm, and Ono Pharm, and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from Kyowa Kirin, Torii Pharm, Daiichi Sankyo, Mitsubishi Tanabe, AstraZeneca, and Astellas Pharm, and a leadership or fiduciary role in other board, society, committee or advocacy group, paid or unpaid at Japan Kidney Association.\u00a0Yusuke Suzuki received research funding from Aurinia, Japan Kidney Association, Mebix, Novartis, Pfizer, Rona Bioscience, Tokiwa, and Travere; consulting fees from Alexion, Alpine, Argenx, BioCryst, Chinook, George Clinical, Novartis, Otsuka, and Renalys; and payment or honoraria for lectures, presentations, speakers bureaus, manuscript writing or educational events from AstraZeneca, Boehringer Ingelheim, Chinook, Daiichi Sankyo, Kyowa Kirin, Mitsubishi Tanabe, Novartis, and Otsuka.","order":2,"name":"Ethics","group":{"name":"EthicsHeading","label":"Conflict of interest"}}]}}